Pay-for-Performance-Verträge bei Arzneimitteln

This procedure is a parliamentary inquiry regarding 'pay-for-performance' contracts for medicines. These agreements link the payment for a drug to the actual health outcomes achieved in patients, aiming to ensure that the healthcare system only pays for treatments that are demonstrably effective. This affects pharmaceutical companies and health insurance providers. It explores changes in how drugs are priced and reimbursed based on clinical success rather than fixed costs.